Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human er-positive breast cancer cells

Journal of Cellular Biochemistry

Volumn 112, Issue 3, 2011, Pages 761-772

  Wȩsierska Ga̧dek, Józefa ^a   Gritsch, David ^a   Zulehner, Nora ^a   Komina, Oxana ^a   Maurer, Margarita ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Activation; Activation of WT P53; Anti Estrogen; Cell cycle; ER ; Estrogen; G2 arrest; P SER118 ER ; Transcriptional elongation

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; ESTROGEN RECEPTOR ALPHA; PROTEIN P53; RNA POLYMERASE II; ROSCOVITINE; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DRUG SYNERGISM; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PURINES; RNA POLYMERASE II; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79951807772     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23004     Document Type: Article

References (83)

1. Ali S, Coombes RC. 2002. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112. (Pubitemid 37328797)
2. Ali S, Metzger D, Bornert JM, Chambon P. 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 12:1153-1160. (Pubitemid 23095864)
3. Aronica SM, Katzenellenbogen BS. 1993. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743-752. (Pubitemid 23207377)
4. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. 1994. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361. (Pubitemid 24168609)
5. Blagosklonny MV, Pardee AB. 2001. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61:4301-4305. (Pubitemid 32685747)
6. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758. (Pubitemid 27458965)
7. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. 1993. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
8. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S. 2000. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 6:127-137.
9. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
10. Couse JF, Korach KS. 1999. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev 20:358-417.
11. Da Silva L, Lakhani SR. 2010. Pathology of hereditary breast cancer. Mod Pathol 23:S46-S51.
12. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. 2008. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res 10:R63.
13. David-Pfeuty T. 1999. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18:7409-7422. (Pubitemid 30035042)
14. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. 1997. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518-526. (Pubitemid 27060442)
15. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K. 2002. Downregulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene 21:8843-8851. (Pubitemid 36132404)
16. Dickson RB, Stancel GM. 2000. Chapter 8: Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000:135-145.
17. Enmark E, Gustafsson JA. 1999. Oestrogen receptors-An overview. J Intern Med 246:133-138.
18. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr., O'Connor PM. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
19. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. 2009. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77.
20. Fujita M, Urano T, Horie K, Ikeda K, Tsukui T, Fukuoka H, Tsutsumi O, Ouchi Y, Inoue S. 2002. Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts. Biochem Biophys Res Commun 299:222-228. (Pubitemid 35373701)
21. Galons H, Oumata N, Meijer L. 2010. Cyclin-dependent kinase inhibitors: A survey of recent patent literature. Expert Opin Ther Pat 20:377-404.
22. Gritsch D, Maurer M, Zulehner N, Wesierska-Gadek J. 2011. Tamoxifen enhances th anti-proliferative effect of roscovitine, a selective CDK inhibitor, on himan ER-positive breast cancer cells. J Exp Ther Oncol 9:37-45.
23. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M. 1997. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40:408-412. (Pubitemid 27080019)
24. Hopp TA, Fuqua SA. 1998. Estrogen receptor variants. J Mammary Gland Biol Neoplasia 3:73-83. (Pubitemid 128513221)
25. Janicke RU, Sprengart ML, Wati MR, Porter AG. 1998. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360. (Pubitemid 28183012)
26. Jazaeri O, Shupnik MA, Jazaeri AA, Rice LW. 1999. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol 74:38-47. (Pubitemid 29331165)
27. Joel PB, Traish AM, Lannigan DA. 1995. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol 9:1041-1052.
28. Joel PB, Traish AM, Lannigan DA. 1998. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273:13317-13323. (Pubitemid 28246906)
29. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494.
30. Katzenellenbogen JA, Katzenellenbogen BS. 1996. Nuclear hormone receptors: Ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3:529-536. (Pubitemid 26324165)
31. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. 1996. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131. (Pubitemid 26042544)
32. Key TJ, Verkasalo PK, Banks E. 2001. Epidemiology of breast cancer. Lancet Oncol 2:133-140. (Pubitemid 33585924)
33. Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68:1-9. (Pubitemid 35418300)
34. Lapenna S, Giordano A. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566.
35. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. 1994. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466.
36. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Dieras V, Raymond E. 2010. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46:3243-3250.
37. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. 2007. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246. (Pubitemid 46640570)
38. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. 1995. The nuclear receptor superfamily: The second decade. Cell 83:835-839.
39. Matthews J, Gustafsson JA. 2003. Estrogen signaling: A subtle balance between ER alpha and ER beta. Mol Interv 3:281-292.
40. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527-536. (Pubitemid 27060443)
41. Murphy CG, Fornier M. 2010. HER2-positive breast cancer: Beyond trastuzumab. Oncology (Williston Park) 24:410-415.
42. Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M, Watson PH. 2009. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J Steroid Biochem Mol Biol 114:90-95.
43. Nathanson KL, Wooster R, Weber BL. 2001. Breast cancer genetics: What we know and what we need. Nat Med 7:552-556. (Pubitemid 32448321)
44. Negrini S, Gorgoulis VG, Halazonetis TD. 2010. Genomic instability-An evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220-228.
45. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
46. Riggs BL, Hartmann LC. 2003. Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice. N Engl J Med 348:618-629. (Pubitemid 36210865)
47. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. 2004. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:2012-2017. (Pubitemid 40128767)
48. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. 2010. CDK inhibitors: From the bench to clinical trials. Curr Drug Targets 11:279-290.
49. Russo IH, Russo J. 1998. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49-61. (Pubitemid 128513219)
50. Schmid G, Wojciechowski J, Wesierska-Gadek J. 2005. Advantage of a baculovirus expression system for protein-protein interaction studies. Involvement of posttranslational phosphorylation in the interaction between wt p53 protein and poly(ADP-ribose) polymerase-1. Acta Biochim Pol 52:713-719.
51. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. 1992. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355-361.
52. Senderowicz AM. 2001. Cyclin-dependent kinase modulators: A novel class of cell cycle regulators for cancer therapy. Cancer Chemother Biol Response Modif 19:165-188.
53. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512. (Pubitemid 29297917)
54. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. 2002. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110:633-641. (Pubitemid 34988787)
55. Smith CL. 1998. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58:627-632. (Pubitemid 28117059)
56. Sutherland RL, Musgrove EA. 2004. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9:95-104. (Pubitemid 39137499)
57. Sutherland RL, Musgrove EA. 2009. CDK inhibitors as potential breast cancer therapeutics: New evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 11:112.
58. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, Meijer L. 1994. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224:771-786. (Pubitemid 24282865)
59. Vindelov LL. 1977. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. Virchows Arch B Cell Pathol 24:227-242.
60. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P. 1985. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82:7889-7893. (Pubitemid 16179869)
61. Washburn T, Hocutt A, Brautigan DL, Korach KS. 1991. Uterine estrogen receptor in vivo: Phosphorylation of nuclear specific forms on serine residues. Mol Endocrinol 5:235-242. (Pubitemid 21923687)
62. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. 2006. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 66:10162-10170. (Pubitemid 44672071)
63. Wesierska-Gadek J, Schmid G. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80:85-103.
64. Wesierska-Gadek J, Bohrn E, Herceg Z, Wang ZQ, Wurzer G. 2000. Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors. J Cell Biochem 78:681-696. (Pubitemid 30620713)
65. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101:128-136. (Pubitemid 34970904)
66. Wesierska-Gadek J, Gueorguieva M, Wojciechowski J, Horky M. 2004a. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: A comparison of the effects exerted by roscovitine and olomoucine. Pol J Pharmacol 56:635-641. (Pubitemid 40123666)
67. Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A. 2004b. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64:4487-4497. (Pubitemid 38856920)
68. Wesierska-Gadek J, Gueorguieva M, Horky M. 2005a. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4:113-124. (Pubitemid 40276781)
69. Wesierska-Gadek J, Gueorguieva M, Ranftler C, Zerza-Schnitzhofer G. 2005b. A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death. J Cell Biochem 96:1-7. (Pubitemid 41420095)
70. Wesierska-Gadek J, Schreiner T, Gueorguieva M, Ranftler C. 2006. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. J Cell Biochem 98:1367-1379. (Pubitemid 44141844)
71. Wesierska-Gadek J, Schmitz ML, Ranftler C. 2007a. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100:865-874.
72. Wesierska-Gadek J, Schreiner T, Maurer M, Waringer A, Ranftler C. 2007b. Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine. Cell Mol Biol Lett 12:280-293. (Pubitemid 46786634)
73. Wesierska-Gadek J, Gueorguieva M, Komina O, Schmid G, Kramer MP. 2008a. Signaling of DNA damage is not sufficient to induce p53 response: (Re)activation of wt p53 protein strongly depends on cellular context. J Cell Biochem 103:1607-1620. (Pubitemid 351490726)
74. Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H. 2008b. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol 76:1503-1514.
75. Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. 2008c. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 105:1161-1171.
76. Wesierska-Gadek J, Borza A, Komina O, Maurer M. 2009a. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: Bi-functionality increases its therapeutic potential. Acta Biochim Pol 56:495-501.
77. Wesierska-Gadek J, Borza A, Walzi E, Krystof V, Maurer M, Komina O, Wandl S. 2009b. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem 106:937-955.
78. Wesierska-Gadek J, Hackl S, Zulehner N, Maurer M, Komina O. 2010a. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors. J Cell Biochem 112:273-288.
79. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. 2010b. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 226:341-349.
80. Wȩsierska-Ga̧dek J, Chamrád I, Kryštof V. 2009c. Novel potent pharmacological cyclin-dependent kinase inhibitors. Future Med Chem 1:1561-1581.
81. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106:486-495. (Pubitemid 36969788)
82. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 11:174-183.
83. Zulehner N, Maurer M, Wesierska-Gadek J. 2011. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on himan breast cancer cells differing in expression of ER. J Exp Ther Oncol 9:17-25.